Skip to main content

Table 2 Frequency of clinical manifestations of congenital toxoplasmosis in newborns from mothers treated with spiramycin (Group 1) and from untreated mothers (Group 2)

From: Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy

Any of the following clinical signs Group 1 Group 2 pa
  (N = 27) (N = 19)  
  n% n%  
Presence 8 (29,63) 13 (68,42) 0,0963
Cerebral calcification 1 (3,70) 3 (15,79) 0,2190
Hydrocephalus - 5 (26,32) 0,0181
Microcephaly - 2 (10,53) 0,1862
Blindness - 2 (10,53) 0,1862
Chorioretinitis 1 (3,70) 3 (15,79) 0,2190
Corticosubcortical dysfunction 2 (7,40) 3 (15,79) 0,3677
Systemic toxoplasmosis - 1 (5,26) 0,4255
Optic neuropathy - 4 (21,05) 0,0384
Hepatosplenomegaly - 2 (10,53) 0,1862
Hearing dysfunction 4 (14,80) 1 (5,26) 0,3402
Generalized lymphoglandular form 1 (3,70) - 0,5957
  1. aFisher’s Exact Test.
  2. (Goiânia-GO, Brazil, 2012).
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us